证券代码：301080 证券简称：百普赛斯 北京百普赛斯生物科技股份有限公司 投资者关系活动记录表 编号：2022-002 | --- | --- | --- | --- | |-------------------------|-------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

北京百普赛斯生物科技股份有限公司 2022 年第三季度报告 证券代码：301080 证券简称：百普赛斯 公告编号：2022-060 北京百普赛斯生物科技股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 1 北京百普赛斯生物科技股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |------------------------------------------------------|------------------|----------------------- ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥228,615,299.34, representing a 30.55% increase compared to ¥175,119,565.46 in the same period last year[27]. - The net profit attributable to shareholders for the first half of 2022 was ¥108,877,039.23, a 50.99% increase from ¥72,106,975.88 in the previous year[27]. - The net cash flow from operating activities was ¥64,186,005.60, up 20.66% from ¥53,193,589.53 in the same period last year[27]. - Basic earnings per share increased to ¥1.3610, a rise of 13.51% from ¥1.1990 in the previous year[27]. - The net profit after deducting non-recurring gains and losses was ¥109,170,998.37, which is a 51.46% increase from ¥72,080,038.47 in the same period last year[27]. - The total revenue for the first half of 2022 reached ¥22,861.53 million, representing a 30.55% increase compared to ¥17,511.96 million in the same period of 2021[44]. - The company reported a significant increase in financial expenses, with a change of -1,503.72% to -¥28,877,852.93, primarily due to foreign exchange gains from currency fluctuations[67]. - The total operating profit reached CNY 120,988,367.54, up from CNY 82,721,257.07, reflecting a growth of approximately 46.1%[197]. - The company reported a total profit of CNY 121,115,446.99, compared to CNY 82,721,355.38 in the previous period, indicating an increase of around 46.3%[197]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,592,444,488.98, reflecting a 1.87% increase from ¥2,544,787,114.48 at the end of the previous year[27]. - The total assets as of June 30, 2022, amounted to CNY 2,690,603,230.54, up from CNY 2,613,461,864.20 at the beginning of the year[194]. - The total liabilities as of June 30, 2022, were CNY 123,095,424.91, compared to CNY 67,544,600.37 at the beginning of the year, reflecting a significant increase[194]. - The company's equity attributable to shareholders was CNY 2,567,507,805.63 as of June 30, 2022, compared to CNY 2,545,917,263.83 at the beginning of the year[194]. - The company's total liabilities included lease liabilities of ¥61,462,261.56, which accounted for 2.37% of total assets[73]. Research and Development - Research and development expenses increased by 92.24% to ¥50,356,222.57, up from ¥26,194,246.04, reflecting the company's commitment to enhancing R&D capabilities[67]. - The company has developed a variety of high-quality recombinant proteins targeting multiple diseases and biomarkers to meet the needs of biopharmaceutical research and production[44]. - The company is committed to becoming a cornerstone enterprise in the biopharmaceutical and health industry[36]. - The company aims to increase new product development in areas such as cell therapy, immune checkpoint products, and infectious disease-related proteins to meet diverse customer needs[61]. Market Position and Products - The company focuses on providing key biological reagents and technical services for the development and production of biopharmaceuticals, cell immunotherapy, and diagnostic reagents[36]. - The company serves top global pharmaceutical companies, including Johnson & Johnson, Pfizer, Novartis, and Roche, as well as leading domestic biopharmaceutical firms[36]. - The main products include recombinant proteins and detection services, along with related products such as kits, antibodies, enzymes, fillers, and culture media[37]. - The company has launched over 2,700 products, including more than 2,400 recombinant proteins, achieving a 40% year-on-year sales growth[58]. Risks and Challenges - The company has outlined potential risks and corresponding measures in its management discussion section[5]. - The company faces risks from rapid technological changes and the need for continuous R&D investment to maintain competitive advantage[103]. - The company is at risk of losing core technical talent due to rising human resource costs and increasing competition for skilled professionals[105]. - The company acknowledges the risk of intensified market competition in the biotechnology sector, necessitating improvements in service levels and market expansion capabilities[104]. Corporate Governance and Management - The company plans to enhance its corporate governance structure and establish effective decision-making and internal management mechanisms[113]. - The company will focus on talent development and recruitment mechanisms to build a high-quality team, ensuring sufficient human resources for future growth[113]. - The company emphasizes the importance of internal control and management efficiency to support its rapid growth and operational scale[108]. Shareholder Information - The company will not distribute cash dividends, issue bonus shares, or increase share capital from capital reserves for the half-year period[122]. - The largest shareholder, Chen Yiding, holds 23.53% of the shares, amounting to 18,827,168 shares[165]. - The company has a total of 9,058 shareholders at the end of the reporting period[165].

Financial Performance - The company's revenue for Q1 2022 reached ¥114,258,131.97, representing a 27.73% increase compared to ¥89,452,306.41 in the same period last year[4] - Net profit attributable to shareholders was ¥53,500,686.51, up 31.66% from ¥40,634,513.23 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥54,160,170.06, reflecting a 33.58% increase from ¥40,544,914.00 in the previous year[4] - Total operating revenue for the current period reached ¥114,258,131.97, a significant increase from ¥89,452,306.41 in the previous period, representing a growth of approximately 27.8%[28] - Net profit for the current period was ¥53,416,447.82, compared to ¥40,538,531.52 in the previous period, reflecting an increase of approximately 31.5%[31] - The company recorded a total profit of ¥59,616,576.98, compared to ¥46,951,773.84 in the previous period, representing an increase of approximately 27%[31] Cash Flow - Cash flow from operating activities showed a significant increase of 130.41%, amounting to ¥36,664,835.38 compared to ¥15,913,195.50 in the same quarter last year[4] - Cash flow from operating activities totaled ¥118,501,065.66, compared to ¥80,225,678.97 in the previous period, showing a growth of approximately 47.6%[35] - The net cash flow from operating activities was $36,664,835.38, an increase from $15,913,195.50 in the previous period, reflecting a growth of approximately 130.5%[38] - The company reported a total cash outflow from operating activities of $81,836,230.28, up from $64,312,483.47 in the previous period[38] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,591,024,719.47, a 1.82% increase from ¥2,544,787,114.48 at the end of the previous year[4] - The total current assets increased slightly to CNY 2,423,163,056.07 from CNY 2,400,599,378.99, reflecting a growth of about 0.94%[21] - The total liabilities decreased to CNY 71,288,310.22 from CNY 78,838,449.58, showing a reduction of about 9%[24] - The total non-current assets increased to CNY 167,861,663.40 from CNY 144,187,735.49, representing a growth of approximately 16.4%[21] Shareholder Equity - Shareholders' equity attributable to the parent company increased by 2.18%, reaching ¥2,520,842,902.22 compared to ¥2,466,970,919.18 at the end of the last year[4] - The equity attributable to the parent company increased to CNY 2,520,842,902.22 from CNY 2,466,970,919.18, marking a growth of approximately 2.2%[27] Earnings and Expenses - Basic earnings per share were ¥0.6688, showing a slight decrease of 1.01% from ¥0.6756 in the same period last year[4] - Research and development expenses surged to ¥22,542,358.36, up from ¥12,549,304.59, indicating an increase of around 80%[28] - Sales expenses rose to ¥20,221,879.67 from ¥12,616,700.20, reflecting an increase of about 60.5%[28] - The cash paid for employee compensation was $32,030,893.88, compared to $22,966,212.90 previously, reflecting an increase of approximately 39.5%[38] - The cash paid for taxes was $17,061,164.54, an increase from $10,881,284.09, indicating a rise of about 56.5%[38] Investment Activities - The total cash inflow from investment activities reached $859,338,417.54, significantly higher than $25,317,374.46 in the prior period[38] - The cash outflow for investment activities amounted to $1,567,967,415.32, compared to $55,427,969.36 previously, indicating a substantial increase in investment spending[38] - The net cash flow from investment activities was -$708,628,997.78, worsening from -$30,110,594.90 in the last period[38] Other Comprehensive Income - The company's other comprehensive income improved to -CNY 3,516,708.79 from -CNY 3,888,005.31, indicating a positive change in financial performance[27] - Other comprehensive income after tax was reported at -¥12,330.87, down from ¥311,029.20 in the previous period[31] Inventory and Payables - The company's inventory rose to CNY 70,053,863.17 from CNY 62,174,843.92, representing an increase of approximately 12.6%[21] - The accounts payable decreased to CNY 7,548,129.64 from CNY 19,858,189.00, a reduction of approximately 62%[24]

Financial Performance - The company reported a total revenue of RMB 800 million for the year 2021, representing a year-on-year increase of 25%[17]. - The net profit attributable to shareholders was RMB 150 million, an increase of 30% compared to the previous year[17]. - The company's operating revenue for 2021 was ¥384,987,712.08, representing a 56.30% increase compared to ¥246,318,612.85 in 2020[24]. - The net profit attributable to shareholders for 2021 was ¥174,214,119.79, a 50.34% increase from ¥115,882,563.52 in 2020[24]. - The net cash flow from operating activities for 2021 was ¥138,007,272.14, an increase of 43.02% compared to ¥96,496,412.20 in 2020[24]. - The total assets at the end of 2021 were ¥2,544,787,114.48, a significant increase of 1,039.04% from ¥223,414,218.19 at the end of 2020[24]. - The company reported a basic and diluted earnings per share of ¥2.7507 for 2021, which is a 42.42% increase from ¥1.9314 in 2020[24]. - In 2021, the company achieved total sales of approximately 2,500 products, including over 2,200 types of recombinant proteins[73]. - The company reported a significant increase in revenue, achieving a year-over-year growth of 25% in the last quarter[199]. Dividend and Cash Management - The company plans to distribute a cash dividend of RMB 15.00 per 10 shares, totaling RMB 120 million[5]. - The net increase in cash and cash equivalents was approximately ¥1.45 billion, reflecting a growth of 3,885.74% due to funds raised from the stock issuance on the Growth Enterprise Market[128]. - Cash and cash equivalents reached 2,007,380,846.75, accounting for 78.88% of total assets, a substantial increase from 41.57% at the beginning of the year[132]. Market Expansion and Growth Strategy - The company has set a revenue target of RMB 1 billion for 2022, indicating a growth expectation of 25%[17]. - The company is expanding its market presence in Southeast Asia, targeting a 15% market share by 2023[17]. - The company plans to enhance its R&D capabilities by establishing new laboratories in Europe and expanding its global R&D footprint through acquisitions, focusing on protein preparation and clinical sample analysis technologies[163]. - Market expansion plans include entering three new international markets by the end of the year[200]. - The company is considering strategic acquisitions to enhance its market position, with a budget of $100 million allocated for potential deals[199]. Research and Development - Research and development expenses increased by 20% to RMB 100 million, focusing on innovative biotechnologies[17]. - The company has established R&D centers in China and the U.S., focusing on continuous technological and production process innovations[52]. - The company has developed multiple core technologies, including membrane protein expression and purification technology, to enhance its product offerings[52]. - The company aims to strengthen technology and product R&D, enhance production capacity, and expand into cell therapy and clinical sample analysis over the next 3-5 years[156]. - R&D investment reached approximately ¥59.55 million, accounting for 15.47% of operating revenue, an increase from 12.44% in the previous year[123]. Product Development and Offerings - New product launches are expected to contribute an additional RMB 200 million in revenue in 2022[17]. - The company has launched innovative products such as high-activity CD19 target proteins and neutralizing antibody screening kits, tailored to meet complex drug development needs[52]. - The company has developed over 2,200 types of recombinant proteins to support drug development, particularly in targeted and immune therapies for diseases like cancer and autoimmune disorders[63]. - The company has developed high-quality GMP-grade cytokines, such as IL-15 and IL-7, to support clinical research in immune cell therapies[65]. - The company has successfully developed various recombinant protein products targeting cutting-edge tumor immunotherapy, increasing product variety and quality[117]. Customer and Market Insights - User data showed a growth of 40% in active users, reaching 1.2 million by the end of 2021[17]. - Customer satisfaction ratings have improved to 90%, reflecting a 5% increase from the previous quarter[200]. - The sales revenue from products priced above 1 million accounted for 30.17% in 2020, which decreased to 2.30% in 2021[76]. Risk Management and Challenges - The management highlighted potential risks including regulatory changes and market competition, with strategies in place to mitigate these risks[5]. - The company recognizes the risk of increased competition in the bioreagent and technical service industry, necessitating continuous improvement in technology and service capabilities to maintain market position[162]. - The company faces risks related to the rapid technological changes in the biopharmaceutical industry, emphasizing the need for ongoing R&D and talent acquisition to remain competitive[159]. - The company acknowledges the potential impact of U.S.-China trade tensions, with 36% of its overseas revenue coming from the U.S. market in 2021[161]. Corporate Governance and Management - The company is committed to maintaining high standards of corporate governance and transparency in its operations[196]. - The company maintains independence from its controlling shareholders in terms of assets, personnel, finance, organization, and business operations[180]. - The company has established an independent financial department with a complete and standardized accounting system, complying with relevant accounting regulations[181]. - The company has a strong management team with diverse backgrounds in biotechnology and finance, enhancing its operational capabilities[191]. Future Outlook - The company has a robust plan for future growth, including potential market expansions and new product launches[197]. - The company has provided a positive outlook for the next quarter, projecting a revenue growth of 20%[199]. - A new marketing strategy is being implemented, targeting a 30% increase in brand awareness within the next six months[200].

Financial Performance - The company's total revenue for the first three quarters of 2021 reached ¥276,138,160.42, representing a 61.51% increase compared to the same period last year[6] - Net profit attributable to shareholders was ¥121,272,419.85, up 55.93% year-on-year[11] - Revenue from non-COVID-19 prevention products was ¥203,780,770.75, a significant increase of 75.46% compared to the previous year[6] - Revenue from COVID-19 prevention products amounted to ¥66,319,384.03, reflecting a 32.87% increase year-on-year[6] - The company's basic earnings per share for the third quarter was ¥0.8194, a 38.91% increase compared to the same period last year[11] - Total operating revenue for the third quarter of 2021 reached ¥276,138,160.42, a 61.5% increase from ¥170,971,809.87 in the same period of 2020[28] - Operating profit for the third quarter was ¥135,421,349.55, up 50.9% from ¥89,753,213.95 year-over-year[28] - Net profit attributable to the parent company was ¥121,272,419.85, compared to ¥77,773,071.57 in the previous year, reflecting a growth of 55.8%[31] - The total comprehensive income for the third quarter was ¥120,874,027.61, up from ¥76,451,381.16 year-over-year, reflecting a growth of 58.1%[31] Assets and Liabilities - Total assets at the end of the reporting period were ¥395,315,523.36, marking a 76.94% increase from the end of the previous year[11] - Total current assets as of September 30, 2021, amount to CNY 293,552,128.27, an increase from CNY 178,958,752.10 as of December 31, 2020[20] - Total liabilities as of September 30, 2021, amounted to ¥74,383,493.65, significantly higher than ¥23,356,216.09 at the end of 2020[24] - Total assets reached CNY 395,315,523.36, up from CNY 223,414,218.19 year-over-year[20] - Total liabilities amounted to 23,356,216.09, a decrease of 17,925,746.39 compared to the previous period[47] - Current liabilities totaled 23,356,216.09, down from 28,659,240.11, indicating a reduction of 5,303,024.02[47] - Non-current liabilities were recorded at 12,622,722.37, consistent with the previous period[47] Shareholder Information - Shareholders' equity increased to ¥321,493,600.95, a rise of 60.50% compared to the previous year-end[11] - Total number of common shareholders at the end of the reporting period is 17, with the top 10 shareholders holding a combined 82.34% of shares[13] - The largest shareholder, Chen Yiding, holds 31.38% of shares, amounting to 18,827,168 shares[13] - The company has no preferred shareholders or restricted shares as of the reporting period[16] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥88,291,930.67, an increase of 33.20% year-on-year[11] - Cash flow from operating activities was ¥267,182,341.95, compared to ¥158,210,982.27 in the same quarter of the previous year, showing a growth of 68.9%[34] - Operating cash inflow totaled CNY 268,202,278.05, an increase of 68.9% compared to CNY 158,842,134.99 in the previous period[37] - Operating cash outflow amounted to CNY 179,910,347.38, up 94.3% from CNY 92,557,311.55 in the prior period[37] - Cash flow from investment activities showed a net outflow of CNY 82,993,830.45, worsening from a net outflow of CNY 29,040,304.42 in the previous period[37] Expenses and Investments - Research and development expenses for the third quarter were ¥40,320,723.17, up from ¥21,579,258.19, indicating a 87.2% increase year-over-year[28] - The company incurred CNY 61,775,731.76 in cash payments to employees, which is a 54.9% increase from CNY 39,898,605.83[37] - The company’s investment cash inflow was CNY 52,038,464.29, a substantial increase from CNY 408,683.71 in the previous period[37] - The company’s cash outflow for purchasing fixed assets and intangible assets was CNY 49,532,294.74, significantly higher than CNY 9,438,988.13 in the prior period[37] Other Information - The weighted average return on net assets was 16.56%, down 7.75% compared to the previous year[11] - The company reported a decrease in other comprehensive income, with a net amount of -¥83,242.91 compared to -¥1,163,018.89 in the previous year[31] - The company has not audited its third-quarter report[50] - The report does not apply to the retrospective adjustment of prior comparative data under the new leasing standards[48] - The company’s capital reserve stands at 55,824,039.12, unchanged from the previous period[47] - The company’s undistributed profits are recorded at 73,386,652.53, remaining stable compared to the previous period[47]